Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs

Croft, SL; Coombs, GH; (2003) Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs. Trends in parasitology, 19 (11). pp. 502-8. ISSN 1471-4922 DOI: https://doi.org/10.1016/j.pt.2003.09.008

Full text not available from this repository. (Request a copy)


The chemotherapy currently available for leishmaniasis is far from satisfactory. Resistance to the pentavalent antimonials, which have been the recommended drugs for the treatment of both visceral (VL) and cutaneous leishmaniasis (CL) for >50 years, is now widespread in India. Although new drugs have become available in recent years for the treatment of VL, including AmBisome((R)), the excellent but highly expensive liposomal formulation of amphotericin B, and the oral drug miltefosine, which has now been registered in India, treatment problems remain. Parenteral and topical formulations of the aminoglycoside paromomycin offer potential treatments for VL and CL, respectively. The search for new drugs continues, with bisphosphonates, for example, risedronate and pamidronate, and plant derivatives such as licochalcone A and quinoline alkaloids being reported to have activity against experimental animal infections. The immunomodulator imiquimod has proved to be an adjunct for CL therapy. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Antimicrobial Resistance Centre (AMR)
Leishmaniasis Group
Malaria Centre
Neglected Tropical Diseases Network
PubMed ID: 14580961
Web of Science ID: 186594700005
URI: http://researchonline.lshtm.ac.uk/id/eprint/15839


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item